(64)CuCl2 PET/CT in prostate cancer relapse

Arnoldo Piccardo, Francesco Paparo, Matteo Puntoni, Sergio Righi, Gianluca Bottoni, Lorenzo Bacigalupo, Silvia Zanardi, Andrea DeCensi, Giulia Ferrarazzo, Monica Gambaro, Filippo Grillo Ruggieri, Fabio Campodonico, Laura Tomasello, Luca Timossi, Simona Sola, Egesta Lopci, Manlio Cabria

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available, clinical or laboratory response and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions and radiation dosimetry of (64)CuCl2 were evaluated. Results: From a dosimetric point-of view, an administered dose of 200 MBq for (64)CuCl2 translates into 5.7mSv of effective dose. Unlike (18)F-Choline, (64)CuCl2 is not excreted nor accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum (64)CuCl2 uptake at the sites of PCa relapse was observed one hour after tracer injection. In our cohort, (64)CuCl2-PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of (18)F-Choline-PET/CT and mpMRI were 56% and 74% respectively. The difference between the DRs of (64)CuCl2-PET/CT and (18)F-Choline-PET/CT was statistically significant (p<0.001). Interestingly, on considering PSA value, (64)CuCl2-PET/CT had a higher DR than (18)F-Choline-PET/CT in patients with PSA <1 ng/ml . Conclusion: The biodistribution of (64)CuCl2 is more suitable than that of (18)F-Choline for exploring the pelvis and prostatic bed. The (64)CuCl2 effective dose is similar to those of other established PET tracers. In patients with biochemical relapse and a low PSA level, (64)CuCl2-PET/CT shows a significantly higher DR than (18)F-Choline-PET/CT.

Original languageEnglish
JournalJournal of Nuclear Medicine
DOIs
Publication statusE-pub ahead of print - Sep 8 2017

Fingerprint

Prostatic Neoplasms
Recurrence
Choline
Radiometry
cupric chloride
Magnetic Resonance Imaging
Pelvis
Urinary Tract
Radiotherapy
Injections

Keywords

  • Journal Article

Cite this

Piccardo, A., Paparo, F., Puntoni, M., Righi, S., Bottoni, G., Bacigalupo, L., ... Cabria, M. (2017). (64)CuCl2 PET/CT in prostate cancer relapse. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.117.195628

(64)CuCl2 PET/CT in prostate cancer relapse. / Piccardo, Arnoldo; Paparo, Francesco; Puntoni, Matteo; Righi, Sergio; Bottoni, Gianluca; Bacigalupo, Lorenzo; Zanardi, Silvia; DeCensi, Andrea; Ferrarazzo, Giulia; Gambaro, Monica; Grillo Ruggieri, Filippo; Campodonico, Fabio; Tomasello, Laura; Timossi, Luca; Sola, Simona; Lopci, Egesta; Cabria, Manlio.

In: Journal of Nuclear Medicine, 08.09.2017.

Research output: Contribution to journalArticle

Piccardo, A, Paparo, F, Puntoni, M, Righi, S, Bottoni, G, Bacigalupo, L, Zanardi, S, DeCensi, A, Ferrarazzo, G, Gambaro, M, Grillo Ruggieri, F, Campodonico, F, Tomasello, L, Timossi, L, Sola, S, Lopci, E & Cabria, M 2017, '(64)CuCl2 PET/CT in prostate cancer relapse', Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.117.195628
Piccardo A, Paparo F, Puntoni M, Righi S, Bottoni G, Bacigalupo L et al. (64)CuCl2 PET/CT in prostate cancer relapse. Journal of Nuclear Medicine. 2017 Sep 8. https://doi.org/10.2967/jnumed.117.195628
Piccardo, Arnoldo ; Paparo, Francesco ; Puntoni, Matteo ; Righi, Sergio ; Bottoni, Gianluca ; Bacigalupo, Lorenzo ; Zanardi, Silvia ; DeCensi, Andrea ; Ferrarazzo, Giulia ; Gambaro, Monica ; Grillo Ruggieri, Filippo ; Campodonico, Fabio ; Tomasello, Laura ; Timossi, Luca ; Sola, Simona ; Lopci, Egesta ; Cabria, Manlio. / (64)CuCl2 PET/CT in prostate cancer relapse. In: Journal of Nuclear Medicine. 2017.
@article{9f32b57577a1423eb1399e50a2184053,
title = "(64)CuCl2 PET/CT in prostate cancer relapse",
abstract = "To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available, clinical or laboratory response and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions and radiation dosimetry of (64)CuCl2 were evaluated. Results: From a dosimetric point-of view, an administered dose of 200 MBq for (64)CuCl2 translates into 5.7mSv of effective dose. Unlike (18)F-Choline, (64)CuCl2 is not excreted nor accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum (64)CuCl2 uptake at the sites of PCa relapse was observed one hour after tracer injection. In our cohort, (64)CuCl2-PET/CT proved positive in 41 of 50 patients, with an overall DR of 82{\%}. The DRs of (18)F-Choline-PET/CT and mpMRI were 56{\%} and 74{\%} respectively. The difference between the DRs of (64)CuCl2-PET/CT and (18)F-Choline-PET/CT was statistically significant (p<0.001). Interestingly, on considering PSA value, (64)CuCl2-PET/CT had a higher DR than (18)F-Choline-PET/CT in patients with PSA <1 ng/ml . Conclusion: The biodistribution of (64)CuCl2 is more suitable than that of (18)F-Choline for exploring the pelvis and prostatic bed. The (64)CuCl2 effective dose is similar to those of other established PET tracers. In patients with biochemical relapse and a low PSA level, (64)CuCl2-PET/CT shows a significantly higher DR than (18)F-Choline-PET/CT.",
keywords = "Journal Article",
author = "Arnoldo Piccardo and Francesco Paparo and Matteo Puntoni and Sergio Righi and Gianluca Bottoni and Lorenzo Bacigalupo and Silvia Zanardi and Andrea DeCensi and Giulia Ferrarazzo and Monica Gambaro and {Grillo Ruggieri}, Filippo and Fabio Campodonico and Laura Tomasello and Luca Timossi and Simona Sola and Egesta Lopci and Manlio Cabria",
note = "Copyright {\circledC} 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2017",
month = "9",
day = "8",
doi = "10.2967/jnumed.117.195628",
language = "English",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",

}

TY - JOUR

T1 - (64)CuCl2 PET/CT in prostate cancer relapse

AU - Piccardo, Arnoldo

AU - Paparo, Francesco

AU - Puntoni, Matteo

AU - Righi, Sergio

AU - Bottoni, Gianluca

AU - Bacigalupo, Lorenzo

AU - Zanardi, Silvia

AU - DeCensi, Andrea

AU - Ferrarazzo, Giulia

AU - Gambaro, Monica

AU - Grillo Ruggieri, Filippo

AU - Campodonico, Fabio

AU - Tomasello, Laura

AU - Timossi, Luca

AU - Sola, Simona

AU - Lopci, Egesta

AU - Cabria, Manlio

N1 - Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2017/9/8

Y1 - 2017/9/8

N2 - To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available, clinical or laboratory response and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions and radiation dosimetry of (64)CuCl2 were evaluated. Results: From a dosimetric point-of view, an administered dose of 200 MBq for (64)CuCl2 translates into 5.7mSv of effective dose. Unlike (18)F-Choline, (64)CuCl2 is not excreted nor accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum (64)CuCl2 uptake at the sites of PCa relapse was observed one hour after tracer injection. In our cohort, (64)CuCl2-PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of (18)F-Choline-PET/CT and mpMRI were 56% and 74% respectively. The difference between the DRs of (64)CuCl2-PET/CT and (18)F-Choline-PET/CT was statistically significant (p<0.001). Interestingly, on considering PSA value, (64)CuCl2-PET/CT had a higher DR than (18)F-Choline-PET/CT in patients with PSA <1 ng/ml . Conclusion: The biodistribution of (64)CuCl2 is more suitable than that of (18)F-Choline for exploring the pelvis and prostatic bed. The (64)CuCl2 effective dose is similar to those of other established PET tracers. In patients with biochemical relapse and a low PSA level, (64)CuCl2-PET/CT shows a significantly higher DR than (18)F-Choline-PET/CT.

AB - To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available, clinical or laboratory response and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions and radiation dosimetry of (64)CuCl2 were evaluated. Results: From a dosimetric point-of view, an administered dose of 200 MBq for (64)CuCl2 translates into 5.7mSv of effective dose. Unlike (18)F-Choline, (64)CuCl2 is not excreted nor accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum (64)CuCl2 uptake at the sites of PCa relapse was observed one hour after tracer injection. In our cohort, (64)CuCl2-PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of (18)F-Choline-PET/CT and mpMRI were 56% and 74% respectively. The difference between the DRs of (64)CuCl2-PET/CT and (18)F-Choline-PET/CT was statistically significant (p<0.001). Interestingly, on considering PSA value, (64)CuCl2-PET/CT had a higher DR than (18)F-Choline-PET/CT in patients with PSA <1 ng/ml . Conclusion: The biodistribution of (64)CuCl2 is more suitable than that of (18)F-Choline for exploring the pelvis and prostatic bed. The (64)CuCl2 effective dose is similar to those of other established PET tracers. In patients with biochemical relapse and a low PSA level, (64)CuCl2-PET/CT shows a significantly higher DR than (18)F-Choline-PET/CT.

KW - Journal Article

U2 - 10.2967/jnumed.117.195628

DO - 10.2967/jnumed.117.195628

M3 - Article

C2 - 28887398

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

ER -